Nature’s Sunshine Targets Muscle Preservation in New Redefine Trial

Nature’s Sunshine Products (NATR) announced an update on their ongoing clinical study.

Nature’s Sunshine Products, Inc. (NATR) is launching a new trial on a product called Redefine that aims to protect muscle during dieting. The official study title describes an adaptive, randomized, double-blind, placebo-controlled trial focused on the safety and tolerability of this multi-ingredient nutritional formula, which is significant for the growing weight loss and metabolic health market.

The intervention being tested is Redefine, a dietary supplement that blends HMB, postbiotics and plant extracts. It is designed to help adults keep lean muscle while they cut calories, with the hope of supporting strength and metabolic health as people lose weight.

The study is interventional and randomized, meaning participants are assigned by chance to Redefine or a look-alike placebo. It uses a parallel design with four groups, is double-blind so neither subjects nor care staff know who gets what, and mainly aims to assess safety while also exploring early effects on body composition.

The sponsor submitted the study on February 25, 2026, marking the formal start of the trial process. The record was last updated on March 3, 2026, which signals that the protocol is current, but recruitment has not yet begun and key completion dates will depend on how quickly sites enroll participants.

For investors, this update highlights NATR’s push into science-backed weight management solutions at a time when muscle preservation is a hot topic alongside GLP-1 drugs. While near-term revenue effects are limited, clear safety data and any positive body composition signals could boost sentiment and help NATR stand out against supplement peers and larger nutrition players.

The study is not yet recruiting and remains in progress on the planning side, with further details and updates available on the ClinicalTrials portal.